BioSpace News Archive

Amyotrophic Lateral Sclerosis (ALS) is a debilitating degenerative disease that gradually causes muscle weakness and disability. Health Canada recognizes that patients with ALS and their families are anxious to access drugs that could help.

A study from Mount Sinai West concludes that the overall mortality in septic shock has improved in the decade following the introduction of the Surviving Sepsis Campaign (SSC) guidelines.

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today presented the full results of the long-term cardiovascular outcome trial, CARMELINA®, which studied the impact of Tradjenta® on cardiovascular safety and kidney outcomes in adults with type 2 diabetes at high risk for heart and/or kidney disease.

IntelGenx Corp. today announced that an Abbreviated New Drug Application (“ANDA”) for a generic buccal film product has been submitted to the U.S. Food and Drug Administration (“FDA”) by its partner, Insud Pharma (formerly Chemo Group).

TGF Analytics ranks USANA 4th among “small/mid cap” companies

Assure Holdings Corp. (the “Company” or “Assure”) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services, has appointed Scott Page as an advisor to the Company’s board of directors.

ANI Pharmaceuticals, Inc. today announced the launch of Candesartan Hydrochlorothiazide Tablets, 16mg/12.5mg, 32mg/12.5mg, and 32mg/25mg, an authorized generic of Atacand HCT®.

Firmenich Incorporated announced today that its wholly-owned U.S. subsidiary, Sentry Merger Sub, Inc., commenced the previously announced tender offer to acquire all of the outstanding common stock of Senomyx, Inc.

Ampio Pharmaceuticals, Inc. today provided an update of the ongoing Company activities required to file a Biologics License Application (BLA) for Ampion™ for the treatment of severe Osteoarthritis of the knee (OAK).

Propanc Biopharma, Inc. today announced initiation of European (EP) validation of its lead patent in most major commercial markets in Europe.